Synmosa Biopharma Corp 4114
TPEX · Taiwan · Health Technology
TWD 29.50-0.05 (-0.17%)
Market closed· · TWD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · TWD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
As global markets navigate a landscape marked by rising inflation concerns and geopolitical tensions, the Asian market continues to present intriguing opportunities, particularly in the realm of small-cap stocks. With small-cap and value stocks outperforming their larger counterparts, investors are increasingly drawn to companies that demonstrate resilience and adaptability in the face of economic challenges. In this context, discovering promising stocks involves identifying firms with robust...
As global markets grapple with rising inflation and geopolitical uncertainties, the Asian market continues to present unique opportunities for investors, particularly in the small-cap sector. In this dynamic environment, identifying stocks with strong fundamentals and growth potential can be key to navigating these challenges; Nanjing Develop Advanced Manufacturing is one such company leading a trio of undiscovered gems in Asia.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.